Abstract
Background: The risk for all addictive drug and non-drug behaviors, especially, in the unmyelinated Prefrontal Cortex (PFC) of adolescents, is important and complex. Many animal and human studies show the epigenetic impact on the developing brain in adolescents, compared to adults. Some reveal an underlying hyperdopaminergia that seems to set our youth up for risky behaviors by inducing high quanta pre-synaptic dopamine release at reward site neurons. In addition, altered reward gene expression in adolescents caused epigenetically by social defeat, like bullying, can continue into adulthood. In contrast, there is also evidence that epigenetic events can elicit adolescent hypodopaminergia. This complexity suggests that neuroscience cannot make a definitive claim that all adolescents carry a hyperdopaminergia trait.
Objective: The primary issue involves the question of whether there exists a mixed hypo or hyper - dopaminergia in this population.
Methods: Genetic Addiction Risk Score (GARS®) testing was carried out of 24 Caucasians of ages 12-19, derived from families with RDS.
Results: We have found that adolescents from this cohort, derived from RDS parents, displayed a high risk for any addictive behavior (a hypodopaminergia), especially, drug-seeking (95%) and alcohol- seeking (64%).
Conclusion: The adolescents in our study, although more work is required, show a hypodopaminergic trait, derived from a family with Reward Deficiency Syndrome (RDS). Certainly, in future studies, we will analyze GARS in non-RDS Caucasians between the ages of 12-19. The suggestion is first to identify risk alleles with the GARS test and, then, use well-researched precision, pro-dopamine neutraceutical regulation. This “two-hit” approach might prevent tragic fatalities among adolescents, in the face of the American opioid/psychostimulant epidemic.
Keywords: Adolescents, meso-limbic system, prefrontal cortex, hypodopaminergia, hyperdopaminergia, precision addiction management (PAM), genetic addiction risk score (GARS).
Graphical Abstract
Current Psychopharmacology
Title:Exploration of Epigenetic State Hyperdopaminergia (Surfeit) and Genetic Trait Hypodopaminergia (Deficit) during Adolescent Brain Development
Volume: 10
Author(s): Kenneth Blum*, Abdalla Bowirrat , Marjorie C.G. Lewis, Thomas A. Simpatico , Mauro Ceccanti, Bruce Steinberg, Edward J. Modestino, Panayotis K. Thanos , David Baron, Thomas McLaughlin , Raymond Brewer, Rajendra D. Badgaiyan, Jessica V. Ponce, Lisa Lott and Mark S. Gold
Affiliation:
- Division of Addiction Research and Education, Center for Psychiatry, Medicine, Primary Care (Office of Provost), Western University Health Sciences, Pomona, CA,United States
Keywords: Adolescents, meso-limbic system, prefrontal cortex, hypodopaminergia, hyperdopaminergia, precision addiction management (PAM), genetic addiction risk score (GARS).
Abstract:
Background: The risk for all addictive drug and non-drug behaviors, especially, in the unmyelinated Prefrontal Cortex (PFC) of adolescents, is important and complex. Many animal and human studies show the epigenetic impact on the developing brain in adolescents, compared to adults. Some reveal an underlying hyperdopaminergia that seems to set our youth up for risky behaviors by inducing high quanta pre-synaptic dopamine release at reward site neurons. In addition, altered reward gene expression in adolescents caused epigenetically by social defeat, like bullying, can continue into adulthood. In contrast, there is also evidence that epigenetic events can elicit adolescent hypodopaminergia. This complexity suggests that neuroscience cannot make a definitive claim that all adolescents carry a hyperdopaminergia trait.
Objective: The primary issue involves the question of whether there exists a mixed hypo or hyper - dopaminergia in this population.
Methods: Genetic Addiction Risk Score (GARS®) testing was carried out of 24 Caucasians of ages 12-19, derived from families with RDS.
Results: We have found that adolescents from this cohort, derived from RDS parents, displayed a high risk for any addictive behavior (a hypodopaminergia), especially, drug-seeking (95%) and alcohol- seeking (64%).
Conclusion: The adolescents in our study, although more work is required, show a hypodopaminergic trait, derived from a family with Reward Deficiency Syndrome (RDS). Certainly, in future studies, we will analyze GARS in non-RDS Caucasians between the ages of 12-19. The suggestion is first to identify risk alleles with the GARS test and, then, use well-researched precision, pro-dopamine neutraceutical regulation. This “two-hit” approach might prevent tragic fatalities among adolescents, in the face of the American opioid/psychostimulant epidemic.
Export Options
About this article
Cite this article as:
Blum Kenneth *, Bowirrat Abdalla , Lewis C.G. Marjorie , Simpatico A. Thomas , Ceccanti Mauro , Steinberg Bruce , Modestino J. Edward, Thanos K. Panayotis , Baron David , McLaughlin Thomas , Brewer Raymond, Badgaiyan D. Rajendra, Ponce V. Jessica , Lott Lisa and Gold S. Mark , Exploration of Epigenetic State Hyperdopaminergia (Surfeit) and Genetic Trait Hypodopaminergia (Deficit) during Adolescent Brain Development, Current Psychopharmacology 2021; 10 (3) . https://dx.doi.org/10.2174/2211556010666210215155509
DOI https://dx.doi.org/10.2174/2211556010666210215155509 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chromatin Remodeling Agents for Cancer Therapy
Reviews on Recent Clinical Trials Pathophysiology of Cardiovascular Diseases and the Role of Vitamins, and Herbal Extracts in the Reduction of Cardiovascular Risks
Cardiovascular & Hematological Agents in Medicinal Chemistry From Brain Ischemia-Reperfusion Injury to Possible Sporadic Alzheimers Disease
Current Neurovascular Research TGF-β: Its Role in Asthma and Therapeutic Potential
Current Drug Targets Neonatal Formulations: The Need for a Tailored, Knowledge Driven Approach
Current Pharmaceutical Design Lipidomics as Tools for Finding Biomarkers of Intestinal Pathology: From Irritable Bowel Syndrome to Colorectal Cancer
Current Drug Targets Left Ventricular Hypertrophy in Isolated Aortic Stenosis: Primetime for the Ventricle
Current Pharmaceutical Biotechnology Antimicrobial Peptides and Peptidomimetics - Potent Therapeutic Allies for Staphylococcal Infections
Current Pharmaceutical Design LHON: Mitochondrial Mutations and More
Current Genomics Metal Complexes, their Cellular Targets and Potential for Cancer Therapy
Current Pharmaceutical Design Potential Therapeutic Effects of Na+/Ca2+ Exchanger Inhibition in Cardiac Diseases
Current Medicinal Chemistry Metabotropic Glutamate Receptors in the Control of Mood Disorders
CNS & Neurological Disorders - Drug Targets Bacterial Translocation, Microcirculation Injury and Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued) Angiotensin-Converting Enzyme - New Insights into Structure, Biological Significance and Prospects for Domain-Selective Inhibitors
Current Enzyme Inhibition Inhaled Insulin and the Lung
Current Medicinal Chemistry Heat Shock Paradox and a New Role of Heat Shock Proteins and their Receptors as Anti-Inflammation Targets
Inflammation & Allergy - Drug Targets (Discontinued) Do Adenosine Receptors Offer New Therapeutic Options for Diabetic Nephropathy?
Current Vascular Pharmacology Comparison of Bone Mineral Density in Common Variable Immunodeficiency and X-Linked Agammaglobulinaemia Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Multifunctional Nanoparticles, Nanocages and Degradable Polymers as a Potential Novel Generation of Non-Invasive Molecular and Cellular Imaging Systems
Recent Patents on Nanotechnology